Skip to content

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00505830
Enrollment
450
Registered
2007-07-25
Start date
2007-07-31
Completion date
2009-07-31
Last updated
2007-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asperger Syndrome, Autism

Keywords

Asperger Syndrom, Autism Quotient, French version, screening, diagnostic test, accuracy

Brief summary

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50. The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire. Secondary objectives are to: Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS. Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents. Define the threshold of positivity for the 3 questionnaires.

Detailed description

4 groups of participants will be screened with the questionnaires: Group 1: 50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ \>85. Group 2: 50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70\<IQ\<84. Group 3: 50 adolescents with psychiatric disorders. Group 4: Sample of 50 healthy adolescents selected randomly from 200. The questionnaires are given to the parents of adolescents during the first meeting. Parents are invited to send them back to the clinical investigation centre of Lyon (France). Multicentre study: 8 clinical centres and 18 paediatricians

Interventions

OTHERquestionnaires

Primary outcome: Autism Spectrum Quotient (AQ) Secondary outcome measure: Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Sponsors

Joint Clinical Research Center
CollaboratorOTHER
Groupe Francais d'Epidemiologie Psychiatrique
Lead SponsorOTHER

Study design

Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

Group 1 (AS/HFA) and 2 (AS/classic autism) : * Boys and girls aged 12 to 18 * Patients with autism or Asperger syndrome according to the diagnostic criteria (ICD 10) * Patients receiving education in an ordinary school * IQ\>70 Group 3 (adolescents with psychiatric disorders): * Boys and girls aged 12 to 18 * Patients hospitalized on a psychiatric ward or at a psychiatrics patient visit or psychiatric consultation wit hout autistic syndrome * Patients receiving education in an ordinary school when not in hospital Group 4 (adolescent without psychiatric syndrome): * Boys and girls aged 12 to 18 * Patients receiving education in an ordinary school

Exclusion criteria

For all groups : * Problem with language or comprehension * Participants who have not given their consent

Countries

France

Contacts

Primary ContactJean-Pierre Vignat, MDH
jpvignat@ch-st-jean-de-dieu-lyon.fr+33 4 37 90 11 75

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026